CORRECTION article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Correction: Strategies of Neoadjuvant Therapy in Esophageal Cancer: A Study on the Effects of Treatment Frequency and Surgery Interval
Provisionally accepted
Huilai Lv1*
Bisong Chen1
Chunyue Gai1
Liu Yu1
Weilu Ding1
Mingbo Wang2Kangbo Sun1Fan Zhang2Yonggang Zhu1Zhenhua Li1
Ziqiang Tian1- 1The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
- 2Hebei Key Laboratory of Accurate Diagnosis and Comprehensive Treatment of Esophageal Cancer, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Correction on: Lv H, Chen B, Gai C, Liu Y, Ding W, Wang M, Sun K, Zhang F, Zhu Y, Li Z and Tian Z (2025) Strategies of neoadjuvant therapy in esophageal cancer: a study on the effects of treatment frequency and surgery interval. In the published article, there was a mistake in Section 3.8 "Subgroup analysis". The two versions of the text before and after the revisions made during the "Author's Proof" stage were displayed simultaneously in two separate paragraphs in Section 3.8.A correction has been made to the Section 3.8 "Subgroup analysis": "Subgroup analyses (Tables 4 and5) indicated that a surgery interval of <6 weeks was associated with improved DFS (HR=2.96, 95% CI: 1.16-7.56, p=0.023). Overall survival (OS) showed a concordant trend but did not reach statistical significance (HR=2.65, 95% CI: 0.93-7.60, p=0.069). In stratified analyses, statistically significant DFS differences were observed in the following subgroups: male sex (HR=2.95, 95% CI: 1.03-8.47, p=0.044), cT3-4 (HR=2.99, 95% CI: 1.15-7.76, p=0.024), cN1-3 (HR=5.86, 95% CI: 1.40-24.55, p=0.016), clinical stage III-IV (HR=3.95, 95% CI: 1.19-13.13, p=0.025), M0 (HR=2.92, 95% CI: 1.14-7.47, p=0.025), squamous cell carcinoma (HR=3.06, 95% CI: 1.20-7.81, p=0.020), and postoperative ypT3-4 (HR=3.03, 95% CI: 1.04-8.79, p=0.042). Patients without a pathological complete response (pCR) likewise demonstrated a significant difference (HR=3.25, 95% CI: 1.15-9.18, p=0.026). The corresponding OS effects in these key subgroups were generally directionally consistent but mostly nonsignificant, suggesting that larger cohorts or longer follow-up are required for confirmation. Notably, the number of treatment cycles showed no significant interaction with either OS or DFS (interaction p=0.565 for OS; p=0.42 for DFS), indicating a limited impact of cycle number on survival outcomes."The original version of this article has been updated.
Keywords: esophageal squamous cell carcinoma, neoadjuvant chemoimmunotherapy, Surgical interval, treatment cycles, Disease-Free Survival
Received: 22 Oct 2025; Accepted: 06 Nov 2025.
Copyright: © 2025 Lv, Chen, Gai, Yu, Ding, Wang, Sun, Zhang, Zhu, Li and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huilai Lv, 48001686@hebmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.